Rett syndrome – Mecp2 Mouse Model (Mecp2tm1.1Bird/J)
Test your immunomodulatory compound in the NOD mouse model of autoimmune type 1 diabetes
Key Characteristics of Mecp2 Mouse Rett Syndrome Model for Preclinical Research
The Mecp2 mouse model is the most widely used preclinical model for efficacy testing and is extensively characterized in the scientific literature (originally described by Guy et al., 2001). Representing a conventional knock-out model, exons 3 and 4 are deleted in mecp2 mice, leading to a loss-of-function of the MECP2 protein and recapitulation of the core neurological phenotypes of Rett syndrome, including seizure-like activity detected via EEG (Fallah et al., 2020).
InnoSer’s in-house validation reproduced and extended previously reported findings in the Mecp2 model (Wither et al., 2018), demonstrating characteristic spike-and-wave discharges (SWDs), an EEG pattern associated with seizure activity in Rett syndrome patients. Importantly, Mecp2 mice respond to levetiracetam and lamotrigine, two of the commonly prescribed antiepileptic drugs (AEDs) for patients with Rett syndrome (Rashid et al., 2025).
The Mecp2 knock-out mouse model therefore arises as a suitable model for preclinical efficacy testing of therapeutics targeting disease mechanisms, namely seizure-related phenotypes, downstream of MECP2 deficiency, and independent of the underlying patient mutation.
✓ InnoSer’s scientific team has confirmed and extended findings of the EEG phenotypes in the Mecp2 bird mouse model and showed responsiveness to the commonly prescribed AEDs, Lamotrigine and Levetiracetam
✓ SWDs remain consistently detectable until the oldest age tested, 27 weeks of age, enabling longitudinal EEG assessment and providing a robust treatment window for efficacy evaluation of novel therapeutics
As a preclinical CRO with expertise in performing preclinical efficacy studies across multiple rare genetic disorders, InnoSer offers the scientific expertise, flexibility, and fast study start times to support your drug development programme. Preclinical efficacy studies using the Mecp2 mouse model form a key part of our expertise in rare genetic neurological disorder models, including Fragile X syndrome, vanishing white matter (eIF2B), STXBP1 encephalopathy, Kabuki Syndrome, Phelan-McDermid syndrome, TSC, and Angelman syndrome.
Evaluate your compound’s therapeutic efficacy using EEG as a translational biomarker
Building on our established approach for detecting SWDs in the Stxbp1 mouse model, InnoSer’s research team demonstrated a robust SWD phenotype in Mecp2 mice.
At InnoSer, EEG recordings are integrated with video monitoring and accelerometry readings, enabling simultaneous assessment of electrophysiological, behavioral, and movement phenotypes. This supports objective, reproducible, and longitudinal efficacy studies in the Mecp2 mouse model.
Whether you are developing a Rett syndrome therapy, an antiepileptic treatment, or a broader therapeutic approach for DEEs, InnoSer’s expertise can provide quantitative, longitudinal efficacy endpoints to strengthen your data package.
A) Schematic overview of InnoSer’s EEG setup; learn more about our platform here. B) In Mecp2 mice, we detect SWDs that are associated with movement arrest, suggestive of an absence seizure phenotype.
InnoSer’s validation data of the NOD mouse model
Female heterozygous Mecp2 knock-out mice exhibit spontaneous spike-wave discharges (SWDs), supporting the use of EEG for translational preclinical efficacy studies in the Mecp2 mouse model to evaluate novel therapeutics for Rett syndrome.
Female heterozygous Mecp2 knockout mice display pronounced spike-wave discharges (SWDs) in the frontal cortex, extending findings previously reported in the Mecp2 mouse model. A previous study described predominantly short, spontaneous cortical discharges of approximately 1–3 seconds, often associated with behavioural pausing and consistent with an absence-like phenotype (Wither et al., 2018). InnoSer’s EEG platform further characterizes this phenotype as robust and longitudinally detectable to at least 27 weeks of age, enabling quantitative assessment of SWD burden and treatment response over time.
Female heterozygous Mecp2 knock-out mice exhibit spontaneous spike-wave discharges (SWDs), which are responsive to treatment with one of the most commonly prescribed anti-epileptic drug (AED), Lamotrigine, supporting the predictive validity of the Mecp2 mouse model and further confirming the translational relevance of EEG-based endpoints for preclinical efficacy testing.
Lamotrigine treatment (50 mg/kg), one of the most commonly prescribed antiepileptic drugs (AEDs) in Rett syndrome patients (Rashid et al., 2025), leads to a significant decrease in spike-wave discharge activity in female Mecp2 (Bird) mice at 20-21 weeks of age. Female heterozygous Mecp2 mice underwent longitudinal EEG monitoring before and after treatment, enabling quantification of SWD frequency.
Key readouts in the Mecp2 mouse model
The People Behind Your Research
Thomas Vogels, PhD
Principal Scientist Neurology
Thomas leads preclinical efficacy studies across InnoSer’s rare neurodevelopmental disease portfolio, with expertise in Rett syndrome and related genetic epilepsies. He supports clients in study design, endpoint selection, and translational strategy for neurodevelopmental disorder programmes.
Ha Thu Pham, PhD
Lead Scientist Neurology
Ha leads the development and implementation of InnoSer’s EEG platform for rare genetic epilepsy models, including the spike-wave discharge (SWD) pipeline in the Mecp2 mouse model. Her expertise in in vivo electrophysiology and quantitative EEG analysis underpins InnoSer’s translational EEG readout offering.
Frequently Asked Questions
Are male or female Mecp2 mice used in preclinical efficacy studies at InnoSer?
As MECP2 is located on the X chromosome, heterozygous female Mecp2 bird knock-out mice exhibit mosaic MECP2 expression whereby around 50% of cells do not express the wild-type mecp2 protein due to X-linked chromosome inactivation, closely mimicking the genetic condition observed in most female Rett syndrome patients.
Male Mecp2 knock-out mice, therefore, present with complete loss-of-function mutations in Mecp2, and in turn exhibit serious and early-onset phenotypes. In human males, Mecp2 mutations are associated with embryonic and/or infantile lethality.
Therefore, heterozygous female Mecp2 knockout mice help more closely recapitulate the genetic mosaicism observed in female Rett syndrome patients, making them the preferred genotype for preclinical efficacy studies.
What types of therapeutics can be evaluated in the Mecp2 mouse model?
The Mecp2 mouse model is a well-established preclinical model for evaluating therapeutic strategies for Rett syndrome and MECP2 deficiency. Because the conventional Mecp2 knockout model features constitutive loss of MECP2 function rather than a patient-specific mutation, it is particularly useful for assessing therapies that aim to restore MECP2 function or target downstream disease mechanisms, namely seizure-related phenotypes.
At InnoSer, the Mecp2 mouse model can be used for preclinical efficacy testing of multiple therapeutic modalities, including:
- Gene therapy and AAV-based gene delivery approaches evaluating whether delivery of functional MECP2 gene can rescue disease-associated phenotypes and improve functional efficacy endpoints in female heterozygous Mecp2 mice.
- ASO-based strategies evaluating whether upregulation of Mecp2 expression from the functional allele rescues phenotypes in female heterozygous mice.
- Small molecules and biologics targeting signalling pathways downstream of Mecp2, including serotonin pathway modulators, IGF-1 analogues, mTOR, BDNF/TrkB, and GABAergic pathways.
- Anti-seizure and epilepsy therapies, potentially relevant for therapeutic platforms targeting developmental and epileptic encephalopathies (DEEs) where seizure and neurophysiological phenotypes are shared therapeutic endpoints
Discover Other Relevant Rare Genetic Disease Models
Discover InnoSer’s Latest Research
Plasma NfL, p-tau217, or Aβ42/40: Which Alzheimer’s disease biomarkers should you include in your preclinical efficacy study?
A practical guide to preclinical Alzheimer’s disease biomarkers panel selection when you’re considering outsourcing to a specialist neurology CRO Biomarkers have transformed Alzheimer's disease clinical trials, enabling diagnosis confirmation for trial eligibility,...
Transgenic Amyloid, Tau, Seeding, or combined Amyloid/Tau pathology mouse models — which is the right one for your drug development program?
A practical guide to model selection when outsourcing your Alzheimer's disease efficacy study to a specialist neurology CRO Choosing the right Alzheimer's disease mouse model is one of the most consequential early decisions in a preclinical drug development program....
Morris Water Maze, Rotarod and beyond: How do you build a comprehensive behavioral test battery when outsourcing your preclinical Alzheimer’s disease efficacy study?
A practical introduction to behavioural test battery selection when outsourcing your Alzheimer's disease efficacy study to a specialist neurology CRO When outsourcing a preclinical Alzheimer's disease efficacy study, behavioral endpoint selection is one of the most...
STXBP1 Foundation and InnoSer validate R122X, a patient-variant mouse model of STXBP1 encephalopathy, to help expand therapeutic opportunities in STXBP1 research
Gene therapies, antisense oligonucleotides (ASOs), RNA editing technologies, and other precision medicine approaches are rapidly transforming the therapeutic landscape for STXBP1 encephalopathy. Currently, around 16 candidate therapies are in development across five...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. InnoSer’s facilities in the Netherlands and Belgium have been AAALAC-accredited since 2016 and 2020, respectively. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com